" We chose to launch one ‘hard’ program with SYnAbs in order to develop an anti-PTM antibody. Indeed, there is no existing available monoclonal antibody for that given modification as of today.
We are delighted with the collaboration with SYnAbs! They know what they are talking about and have considerable experience with antibody production "
- Gaetan Michel, VolitionRx, CEO